BioSpace News Archive

ViAqua’s first product is a functional feed that enhances shrimp health, reducing disease impact and limiting losses in shrimp aquaculture.

Experimental models had enhanced physical activity, socialization and cognitive stimulation early in life

RadNet, Inc. announced that it will host a conference call to discuss its fourth quarter 2019 financial results on Thursday, March 12th, 2020 at 7:30 a.m. Pacific Time.

Feb. 19, 2020 11:00 UTC HUNTINGTON BEACH, Calif.--( BUSINESS WIRE )-- Cicero Diagnostics Inc., a women’s healthcare diagnostic company, is pleased to announce the awarding of a $1 million Phase II SBIR Fast Track grant from the National Institutes of Health (NIH). The grant, titled “SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity” follows completion of Phase I, successfully demonstrating concordance of the protein markers BCL6 and SIRT1 to endometr

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the SVB Leerink Global Healthcare Conference at 10:30 a.m. ET on Thursday, February 27, 2020, in Ne

Feb. 19, 2020 12:00 UTC First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required Integration with the next generation Dexcom G7 CGM system, once available SAN DIEGO & ACTON, Mass.--( BUSINESS WIRE )-- DexCom , Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreem

LAVAL, Quebec , Feb. 19, 2020 /PRNewswire/ -- Fourth-Quarter 2019 Financial Results Revenues of $2.224 Billion GAAP Cash Generated from Operations of $234 Million GAAP Net Loss of $1.516 Billion Adjusted EBITDA (non-GAAP) 1 of $898 Million Full-Year 2019 Financial Results Revenues of $8.601 Billion GAAP Cash Generated from Operat

VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen, has launched Qsymia (phentermine and topiramate extended-release) in the Republic of Korea

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the 9 th Annual SVB Leerink Global Healthcare Conference. The fireside chat will take place on Wednesda

Translate Bio announced that Ronald Renaud, chief executive officer, will present a corporate overview at the following upcoming investor conferences